RT Journal Article
SR Electronic
T1 Role of Blood Lipids in the Shared Genetic Etiology Between Major Depressive Disorder and Myocardial Infarction: A Large-scale Multi-trait Association Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.08.24305481
DO 10.1101/2024.04.08.24305481
A1 Zhu, Yanchen
A1 Wu, Zhengbo
A1 Wang, Yahui
A1 Cui, Zhaorui
A1 Liu, Fani
A1 Hu, Jiqiang
YR 2024
UL http://medrxiv.org/content/early/2024/04/09/2024.04.08.24305481.abstract
AB Background The genetic role of blood lipids (BL) in the shared genetic etiology between major depressive disorder (MDD) and myocardial infarction (MI) has not been fully characterized.Methods We first evaluated genetic associations and causal inferences between MDD, MI and the quantitative traits of BL. To further unravel the underlying genetic mechanisms, we performed multi-trait association analysis to identify novel or pleiotropic genomic risk loci, and shared causal variants for diseases involving BL. Using multiple post-GWAS methods, we explored potential genes, pathways, tissues, cells, and therapeutic targets associated with diseases from different perspectives.Findings We found extensive global and local genetic correlations between MDD, MI and the traits of BL. Mendelian randomization (MR) analyses showed that lipid metabolism mediated 26.5% of the mediating effect of MDD leading to MI. Multi-trait association analysis successfully identified 13 MDD- and 36 MI- novel risk loci which have never been reported before. Notably, many pleiotropic loci and shared causal variants were identified across risk loci for both diseases, such as 11q23.3 (rs117937125) and 12q13.3 (rs188571756), which also colocalized for traits of BL. Pathway enrichment analysis further highlighted shared biological pathways primarily involving synaptic function, arterial development, and lipid metabolism. Lastly, gene-mapping, gene-based, transcriptome-wide and proteome-wide association, and MR-proteomic analyses revealed candidate pathogenic genes and therapeutic targets (such as ANGPTL4 and TMEM106B).Interpretation These findings not only provide novel insights into the role of BL in the comorbidity between MDD and MI, but also benefit the development of preventive or therapeutic drugs for diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Capital Health Research and Development of Special Fund (2020-2-4203).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally obtained as follows:The GWAS summary statistic for major depressive disorder from Psychiatric Genomics Consortium (PGC) was available at https://pgc.unc.edu/. GWAS for myocardial infarction was obtained from the GWAS Catalog website (GCST009541). GWAS for all quantitative traits of blood lipids from Global Lipids Genetics Consortium (GLGC) were available at https://csg.sph.umich.edu/willer/public/glgc-lipids2021. The eQTL from GTEx v8 were available at http://gusevlab.org/projects/fusion/. The plasma pQTL from the UK Biobank Pharma Proteomics Project (UKB-PPP) were obtained through the website https://www.synapse.org/, from deCODE genetics via http://www.decode.com, and from ARIC study via http://nilanjanchatterjeelab.org/pwas/. The DLPFC pQTL were obtained at https://www.synapse.org/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNo novel custom computer code or mathematical algorithm was employed in generating the results pivotal to the derived conclusions.